Literature DB >> 19454110

Bipolar disorder.

John R Geddes1, David Briess.   

Abstract

INTRODUCTION: Bipolar disorder, with mood swings between depression and mania, may affect up to 1.5% of adults, and increases the risk of suicide and disability. Most people improve over time, but two thirds may have residual dysfunction, and at least 40% may have recurrent episodes. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments in people with mania associated with bipolar disorder? What are the effects of treatments in bipolar depression? What are the effects of interventions to prevent relapse of mania or bipolar depression? We searched: Medline, Embase, The Cochrane Library and other important databases up to July 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 60 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antidepressants, carbamazepine, chlorpromazine, clonazepam, cognitive therapy, education, family-focused psychoeducation, gabapentin, haloperidol, lamotrigine, lithium, olanzapine, psychological treatments, quetiapine, risperidone, topiramate, valproate, and ziprasidone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19454110      PMCID: PMC2943789     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  65 in total

Review 1.  Bipolar disorder.

Authors:  Bruno Müller-Oerlinghausen; Anne Berghöfer; Michael Bauer
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

2.  Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.

Authors:  Paul E Keck; Marcio Versiani; Steven Potkin; Scott A West; Earl Giller; Kathleen Ice
Journal:  Am J Psychiatry       Date:  2003-04       Impact factor: 18.112

3.  Family-focused treatment versus individual treatment for bipolar disorder: results of a randomized clinical trial.

Authors:  Margaret M Rea; Martha C Tompson; David J Miklowitz; Michael J Goldstein; Sun Hwang; Jim Mintz
Journal:  J Consult Clin Psychol       Date:  2003-06

4.  Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.

Authors:  Mauricio Tohen; Terence A Ketter; Carlos A Zarate; Trisha Suppes; Mark Frye; Lori Altshuler; John Zajecka; Leslie M Schuh; Richard C Risser; Eileen Brown; Robert W Baker
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

5.  A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year.

Authors:  Dominic H Lam; Edward R Watkins; Peter Hayward; Jenifer Bright; Kim Wright; Natalie Kerr; Gina Parr-Davis; Pak Sham
Journal:  Arch Gen Psychiatry       Date:  2003-02

6.  A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder.

Authors:  David J Miklowitz; Elizabeth L George; Jeffrey A Richards; Teresa L Simoneau; Richard L Suddath
Journal:  Arch Gen Psychiatry       Date:  2003-09

Review 7.  Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders.

Authors:  A Eden Evins
Journal:  J Clin Psychiatry       Date:  2003       Impact factor: 4.384

8.  A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission.

Authors:  Francesco Colom; Eduard Vieta; Anabel Martinez-Aran; Maria Reinares; Jose Manuel Goikolea; Antonio Benabarre; Carla Torrent; Merce Comes; Barbara Corbella; Gemma Parramon; Josep Corominas
Journal:  Arch Gen Psychiatry       Date:  2003-04

9.  Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients.

Authors:  Erwin G Th M Hartong; Peter Moleman; Cees A L Hoogduin; Theo G Broekman; Willem A Nolen
Journal:  J Clin Psychiatry       Date:  2003-02       Impact factor: 4.384

10.  A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.

Authors:  Joseph R Calabrese; Charles L Bowden; Gary Sachs; Lakshmi N Yatham; Kirsten Behnke; Olli-Pekka Mehtonen; Paul Montgomery; John Ascher; Walter Paska; Nancy Earl; Joseph DeVeaugh-Geiss
Journal:  J Clin Psychiatry       Date:  2003-09       Impact factor: 4.384

View more
  1 in total

1.  Lithium bidirectionally regulates depression- and mania-related brain functional alterations without worsening cognitive function in patients with bipolar disorder.

Authors:  Chuanjun Zhuo; Guangdong Chen; Jiayue Chen; Hongjun Tian; Xiaoyan Ma; Qianchen Li; Lei Yang; Qiuyu Zhang; Ranli Li; Xueqin Song; Chunhai Huang
Journal:  Front Psychiatry       Date:  2022-09-15       Impact factor: 5.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.